Cargando…
Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
BACKGROUND: In patients with type-2 diabetes receiving oral antidiabetic drugs (OADs), the addition of insulin is frequently required to achieve sufficient control over blood glucose levels. It is, however, difficult to predict if, when and in which patients insulin therapy will be needed. We aimed...
Autores principales: | Danne, Thomas, Bluhmki, Tobias, Seufert, Jochen, Kaltheuner, Matthias, Rathmann, Wolfgang, Beyersmann, Jan, Bramlage, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597397/ https://www.ncbi.nlm.nih.gov/pubmed/26446863 http://dx.doi.org/10.1186/s12902-015-0051-0 |
Ejemplares similares
-
Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry
por: Bramlage, Peter, et al.
Publicado: (2017) -
Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019) -
Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015) -
An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria
por: Bramlage, Peter, et al.
Publicado: (2023) -
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
por: Seufert, Jochen, et al.
Publicado: (2021)